TB Archives – Page 8 of 47 – Treatment Action Group

Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

Ten Principles for Access to Multi-disease Molecular Diagnostics: A Global Call to Action

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.

Treatment Action Group Adds Three New Board Members

August 23, 2022
Dorrit Walsh

As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

August 1, 2022
Dorrit Walsh

We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

1 / 4 / 6 x 24 Campaign Launched to Rally Energy, Political Will, Funding Needed to Fight Tuberculosis

July 31, 2022
Dorrit Walsh

Against the backdrop of the COVID-19 pandemic and other concurrent global health, economic, social, and political crises, the 1 / 4 / 6 x 24 Campaign, launched during the AIDS conference in Montreal, seeks to improve TB treatment and prevention worldwide based on the latest medical innovations and to reignite the fight to end tuberculosis (TB).

Cover of Pipeline Report 2022. Black cover with grey type and decorative bright green lines

2022 Pipeline Report

July 24, 2022
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

cover that reads TB CAB 10-Year Anniversary Evaluation Report 2011-2021, March 2022, by Andrea DeLuca, also has a black and whilte photo montage of people engaged in meetings and demonstrations

TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast

July 18, 2022
Dorrit Walsh

In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.

Research in Action Awards 2022

July 8, 2022
Dorrit Walsh

Save the date for Tuesday, November 16, 2021! TAG’s 2021 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world. This year we’ll once again gather virtually to ensure this year’s event is safe and open for participation to our allies and friends across the U.S. and world.

Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline

July 1, 2022
Dorrit Walsh

A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

Roundtable on Access to Multi-disease Molecular Diagnostics

June 23, 2022
Dorrit Walsh

On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…